ATE332703T1 - Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung - Google Patents

Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung

Info

Publication number
ATE332703T1
ATE332703T1 AT04713307T AT04713307T ATE332703T1 AT E332703 T1 ATE332703 T1 AT E332703T1 AT 04713307 T AT04713307 T AT 04713307T AT 04713307 T AT04713307 T AT 04713307T AT E332703 T1 ATE332703 T1 AT E332703T1
Authority
AT
Austria
Prior art keywords
wound healing
hsp20
promote wound
reduce scaring
scaring
Prior art date
Application number
AT04713307T
Other languages
English (en)
Inventor
Colleen Brophy
Alyssa Panitch
Catherine Parmiter
Elizabeth Furnish
Padmini Komalavilas
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Application granted granted Critical
Publication of ATE332703T1 publication Critical patent/ATE332703T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
AT04713307T 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung ATE332703T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44895403P 2003-02-21 2003-02-21
US51221103P 2003-10-17 2003-10-17
US53030603P 2003-12-16 2003-12-16

Publications (1)

Publication Number Publication Date
ATE332703T1 true ATE332703T1 (de) 2006-08-15

Family

ID=32931323

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06014290T ATE455553T1 (de) 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
AT04713307T ATE332703T1 (de) 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06014290T ATE455553T1 (de) 2003-02-21 2004-02-20 Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung

Country Status (9)

Country Link
US (3) US8101572B2 (de)
EP (2) EP1594526B1 (de)
AT (2) ATE455553T1 (de)
AU (1) AU2004216241B2 (de)
DE (2) DE602004001509T2 (de)
DK (2) DK1594526T3 (de)
ES (2) ES2268631T3 (de)
PT (1) PT1808179E (de)
WO (1) WO2004075914A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594526B1 (de) 2003-02-21 2006-07-12 Arizona Board Of Regents Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
JP2007508823A (ja) * 2003-10-17 2007-04-12 アリゾナ ボード オブ リージェンツ 新規な熱ショックタンパク質20関連ポリペプチドおよびその使用
MX2009000359A (es) * 2006-07-12 2009-05-08 Univ Arizona Metodos paratratar y limitar trastornos fibroticos y queloides.
ES2594281T3 (es) 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
WO2020167894A1 (en) * 2019-02-12 2020-08-20 Vanderbilt University Polypeptides for restoring endothelial function and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
JP2001278894A (ja) 2000-03-29 2001-10-10 Osamu Ozawa 血液循環障害予防および/または治療用医薬用組成物並びにその有効成分であるペプチド
WO2001098497A1 (en) 2000-06-21 2001-12-27 Amgen, Inc. Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
WO2003018758A2 (en) 2001-08-23 2003-03-06 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
AU2003260668A1 (en) 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
WO2004017912A2 (en) 2002-08-22 2004-03-04 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University, Office Of Technology Collaboration And Licensing Methods for increasing the rate of heart muscle contraction
EP1594526B1 (de) 2003-02-21 2006-07-12 Arizona Board Of Regents Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
JP2007508823A (ja) 2003-10-17 2007-04-12 アリゾナ ボード オブ リージェンツ 新規な熱ショックタンパク質20関連ポリペプチドおよびその使用

Also Published As

Publication number Publication date
EP1808179B1 (de) 2010-01-20
ATE455553T1 (de) 2010-02-15
EP1808179A3 (de) 2007-10-24
ES2338350T3 (es) 2010-05-06
WO2004075914A1 (en) 2004-09-10
US8101572B2 (en) 2012-01-24
EP1594526A1 (de) 2005-11-16
DE602004001509T2 (de) 2007-02-15
US20120238508A1 (en) 2012-09-20
EP1594526B1 (de) 2006-07-12
DK1594526T3 (da) 2006-11-13
DE602004001509D1 (de) 2006-08-24
DK1808179T3 (da) 2010-04-12
EP1808179A2 (de) 2007-07-18
PT1808179E (pt) 2010-03-24
AU2004216241A1 (en) 2004-09-10
DE602004025300D1 (de) 2010-03-11
ES2268631T3 (es) 2007-03-16
US20150072936A1 (en) 2015-03-12
US20100009903A1 (en) 2010-01-14
US8765673B2 (en) 2014-07-01
AU2004216241B2 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
CY1119127T1 (el) Επιτοποι σκληροστινης
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
DE602004017588D1 (de) 2-phenoxy- und 2-phenylsulfanyl-benzenesulfonamid derivate mit ccr3 antagonistischer aktivität zur behandlung von asthma und anderen entzündlichen oder immunologischen erkrankungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
DE602005012905D1 (de) Verwendung von Substanz P zur Mobilisierung und Proliferation mesenchymaler Stammzellen und zur Wundheilung
DE602004016385D1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
DE602004019229D1 (de) Inhibitoren von mitotischem kinesin
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
DE60335018D1 (de) Mittel zur verhinderung von hautalterung
ATE455553T1 (de) Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
ATE363531T1 (de) Claudin polypeptide
ATE472329T1 (de) Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE557092T1 (de) Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60323533D1 (de) Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1594526

Country of ref document: EP